Delving into the Latest Updates on Cal-1 modified CD4+ T lymphocytes with Synapse

Overview

Basic Info

Drug Type

T-lymphocyte cell therapy

Synonyms-

Target-

Mechanism

Cell replacements

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication-

Inactive Indication

Acquired Immunodeficiency Syndrome

Originator Organization

Calimmune, Inc.

Active Organization-

Inactive Organization

Calimmune, Inc.

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral drugs.
Cal-1 is an experimental gene transfer agent designed to inhibit HIV infection through 2 active parts:
Removing a protein named CCR5 from bone marrow and white blood cells
Producing a protein named C46 on bone marrow and white blood cells

Start Date01 Apr 2013

Sponsor / Collaborator

Calimmune, Inc.

100 Clinical Results associated with Cal-1 modified CD4+ T lymphocytes

Login to view more data

100 Translational Medicine associated with Cal-1 modified CD4+ T lymphocytes

Login to view more data

100 Patents (Medical) associated with Cal-1 modified CD4+ T lymphocytes

Login to view more data

100 Deals associated with Cal-1 modified CD4+ T lymphocytes

Login to view more data